Stephanie L. Graff, MD, FACP

Articles

Impact of Trial Data on Clinical Practice

August 10th 2023

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.

Key Findings from the NATALEE Trial

August 3rd 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

Risk of Recurrence

August 3rd 2023

Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.

Clinical Case 2: High-Risk Early-Stage HR+ Breast Cancer

July 27th 2023

Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Selecting Endocrine Therapy in BRCA1/BRCA2+ Breast Cancer

July 27th 2023

Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.

Implementing Trial Data to Our Practice

July 20th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

Dosing CDK 4/6 Inhibitors

July 20th 2023

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

Age-Dependent Results With CDK 4/6 Inhibitors

July 13th 2023

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

Individualizing Care with CDK 4/6 Inhibitors

July 13th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

Key Findings from the monarchE Trial

July 6th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.

Endocrine Therapy for Early-Stage Breast Cancer

July 6th 2023

Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.

Risk Factors and the Treatment Plan

June 29th 2023

Rachel Layman, MD, describes her impression of the case and discusses risk assessment and a treatment plan for the patient.

Clinical Case 1: High-Risk Early-Stage HR+ Breast Cancer

June 29th 2023

Stephanie Graff, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Dr Graff on the Investigation of Datopotamab Deruxtecan in HR+ Breast Cancer and TNBC

May 4th 2023

Stephanie L. Graff, MD, discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive breast cancer and triple-negative breast cancer.

Dr Graff on the Evaluation of Trastuzumab Deruxtecan in HER2-Zero Breast Cancer

April 12th 2023

Stephanie L. Graff, MD, discusses the evaluation of trastuzumab deruxtecan in patients with HER2-zero metastatic breast cancer in the ongoing, phase 2 DESTINY-Breast06 trial.

Dr Graff on Data From HER2CLIMB Exploratory Analysis in HER2+ Breast Cancer With Brain Metastases

April 6th 2023

Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.

Future Directions in Care for HER2+ Breast Cancer

August 15th 2022

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

August 15th 2022

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Dr. Graff on Initial Steps for Treating Metastatic HR-Positive Breast Cancer

August 8th 2022

Stephanie L. Graff, MD, discusses the initial steps for treating patients with metastatic hormone receptor–positive breast cancer.

Novel Treatment Strategies for HER2-Low Breast Cancer

August 8th 2022

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.